Integrated Core Strategies (US) LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-30 4:17 pm Sale | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 1,899,516 4.100% | -1,020,543 (-34.95%) | Filing |
| 2022-01-18 4:55 pm Purchase | 2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,920,059 6.300% | 403,531 (+16.04%) | Filing |
| 2021-12-06 4:44 pm Purchase | 2021-12-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,516,528 5.400% | 487,927 (+24.05%) | Filing |
| 2021-10-22 4:36 pm Purchase | 2021-10-12 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,028,601 4.800% | 2,028,601 (New Position) | Filing |